HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind comparison of a novel indanone diuretic (MK-196) with hydrochlorothiazide in the treatment of essential hypertension.

Abstract
1 The antihypertensive effect and tolerability of MK-196 (10 mg and 15 mg daily) was compared to hydrochlorothiazide (HCT; 50 mg daily) in a 4-week multiclinic, double-blind study involving 42 patients with mild to moderate, essential hypertension. 2 Both doses of MK-196 were as effective and sometimes more effective than HCT in lowering standing and supine systolic and diastolic blood pressures. 3 HCT consistently brought about significant increases in serum uric acid and significant decreases in serum potassium; both doses of MK-196 produced similar but less frequent and smaller changes in both of these parameters. 4 Both doses of MK-196 brought about significant decreases in body weight at Weeks 3 and 4 of drug treatment. 5 Patients taking MK-196 reported fewer adverse clinical reactions (10 mg = 15%; 15 mg = 13% than those taking HCT (21%). 6 MK-196 may offer a therapeutic advantage over HCT as an antihypertensive agent for use in the treatment of mild to moderate, essential hypertension.
AuthorsC E Wilhelmsson, J A Vedin, C Moerlin, P Lund-Johansen, C Vorburger, W Enenkel, P M Lutterbeck, J Bolognese, V J Cirillo, K F Tempero
JournalBritish journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 8 Issue 3 Pg. 261-6 (Sep 1979) ISSN: 0306-5251 [Print] England
PMID387057 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Diuretics
  • Indans
  • Indenes
  • Hydrochlorothiazide
  • indacrinone
Topics
  • Adult
  • Clinical Trials as Topic
  • Diuretics (adverse effects, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Hydrochlorothiazide (adverse effects, therapeutic use)
  • Hypertension (drug therapy, metabolism)
  • Indans (adverse effects, therapeutic use)
  • Indenes (therapeutic use)
  • Male
  • Middle Aged
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: